Philippe Backeljauw
Cincinnati Childrens Hospital Medical Center · Cincinnati Childrens Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Philippe Backeljauw as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03288103 · Growth Hormone Treatment in Patients With Aggrecan (ACAN) DeficiencyChildren's Hospital Medical Center, Cincinnati · completed · Short Stature · principal investigator
- Ph1/Ph2NCT02636270 · IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 DeficiencyChildren's Hospital Medical Center, Cincinnati · completed · Short Stature · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CLINICAL TRIAL: GH IN CHILDREN WITH SHORT STATURE DUE TO GROWTH HORMONE INSENSITM01RR008084 · NCRR · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2005 to 2008 · $2,601 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:47 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.J Clin Endocrinol Metab · 2007171 citationsRCR 4.7
- Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.J Clin Endocrinol Metab · 200475 citationsRCR 2.4
- Adrenal Insufficiency after Chronic Swallowed Glucocorticoid Therapy for Eosinophilic Esophagitis.J Pediatr · 201665 citationsRCR 3.0
- Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I.Horm Res Paediatr · 201336 citationsRCR 1.4
- Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.Horm Res Paediatr · 202028 citationsRCR 2.3
- Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.J Clin Endocrinol Metab · 201727 citationsRCR 1.3
- Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.Muscle Nerve · 202023 citationsRCR 1.5
- Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study.Eur J Endocrinol · 202319 citationsRCR 3.3
- 16 citationsRCR 0.6
- Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.Horm Res Paediatr · 202115 citationsRCR 1.5